A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial Evaluating the Efficacy of Burosumab, an Anti-FGF23 Antibody, in Adults With X-Linked Hypophosphatemia: Week 24 Primary Analysis

on behalf of the AXLES 1 Investigators

Research output: Contribution to journalArticle

64 Scopus citations

Fingerprint Dive into the research topics of 'A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial Evaluating the Efficacy of Burosumab, an Anti-FGF23 Antibody, in Adults With X-Linked Hypophosphatemia: Week 24 Primary Analysis'. Together they form a unique fingerprint.

Medicine & Life Sciences